pharmaceutical investing SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
pharmaceutical investing One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
pharmaceutical investing AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
pharmaceutical investing A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
pharmaceutical investing AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
pharmaceutical investing AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata
pharmaceutical investing AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
pharmaceutical investing The Aesthetics Giants Just Confirmed "Ozempic Face" Is Real - and a Newly Public Regenerative Player Wants to Compete for It
pharmaceutical investing BOTOX® Cosmetic Introduces The Confidence Collective's Entrepreneur Class of 2026
pharmaceutical investing Allergan Aesthetics receives approval for Boey® in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
pharmaceutical investing AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection
pharmaceutical investing AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
America Needs Antimony, and This Nevada Explorer Just Defined One of the Largest Domestic Resources of It
NEVGOLD ANNOUNCES MINERAL RESOURCE: ANTIMONY OF 29,600 TONNES MEASURED & INDICATED AND 48,100 TONNES INFERRED ; 100% OXIDE GOLD OF 181,400 OZS MEASURED & INDICATED AND 1,203,500 OZS INFERRED; STRATEGIC U.S. ANTIMONY RESOURCE
SAGA Metals Reports Assays from R-0047 to R-0049 with Intercepts Including 53.72% Fe2O3, 7.32% TiO2, 0.431% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
